Oxford VR (OVR) a global pioneer in evidence-based virtual reality (VR) therapy, and an integral collaborator in gameChange, a £4 million project funded by the UK National Institute of Health Research (NIHR), has begun the first large-scale multi-site trial to test VR therapy treatment for psychosis to advance its roll out by the NHS and Social Care. GameChange demonstrates the clinical value of OVR’s proprietary development capability which the company has accelerated since its’ 2018 funding round.
The gameChange trial is being led by Daniel Freeman, Professor of Psychology at the University of Oxford. Other collaborators include Oxford Health NHS Foundation Trust, The McPin Foundation, The Royal College of Art, NIHR, MindTech and several NHS mental health trusts. Given the high costs associated with treating psychosis estimated to be in the region of £4 billion by 2026 for NHS England, the automated nature of this treatment means it could provide a low-cost option to complement existing care. The study team will also analyse the cost-effectiveness of the VR therapy and produce a commissioning case and implementation roadmap for VR Therapy to be used in the NHS nationwide.
Psychosis is a serious mental illness which can affect individuals’ thoughts, feelings and behaviours and can have a big impact on a person’s life leading to anxiety and withdrawal from everyday life. For the majority of individuals with psychosis, everyday tasks can become extremely challenging. Work and home life suffer, and mental and physical health deteriorates. Each year the NHS cares for over 200,000 people with psychosis accounting for approximately 30% of total NHS and Social Care expenditure. This patient population has a life expectancy that is 14.5 years shorter than the rest of the population.
The powerful immersive nature of VR technology allows people to experience situations they find troubling in a ‘safe space’ where they know the interaction isn’t real – but the beauty is that the benefits transfer to the real world (OVR published a ground-breaking proof of principle trial in the Lancet in August 2018). The treatment is automated and an avatar clinical coach guides the patient through VR scenarios, helping them to practice techniques to overcome their difficulties. By applying leading-edge gaming technology design to virtual reality treatment scenarios, patients report finding it easier to do this work in the virtual world – and that they even enjoy using the VR application.
Barnaby Perks, Founding CEO of Oxford VR said: “We are at a moment of real change in advancing treatment for serious, complex and costly mental health conditions and gameChange will show how the very best psychological science when combined with scaleable, state-of-the-art VR technology can revolutionise treatment and deliver a superior patient experience. gameChange shows that Oxford VR has the know-how and capacity to go beyond the primary care to create a standard treatment for more challenging and costly mental health conditions.”
The gameChange clinical trial, which is the second phase of a £4 million project funded by the UK National Institute of Health Research (NIHR) to enable state-of-the-art VR therapy for psychosis to be delivered by the NHS. 432 patients have been recruited to participate in the gameChange clinical trial to test VR Therapy for psychosis across and several NHS mental health trusts.
In June 2019, OVR announced its global expansion into Asia with first-of-kind VR-enabled mental health solutions launch in partnership with AXA HK and Chinese University of Hong Kong.